Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: Doxorubicin, cisplatin, irinotecan or topotecan

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2269-2274

  Hardman, W Elaine ^a   Moyer, Mary Pat ^b,c   Cameron, Ivan L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NONE   (United States)

Author keywords

Breast; Cisplatin; Colon; Doxorubicin; Human carcinoma; Irinotecan; Lung; Topotecan; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IRINOTECAN; TOPOTECAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; CISPLATIN; COLONIC NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032774272     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJM, Fodstad O, Langdon S, and Fiebig HH: Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 52: 5940-2547, 1992.
2. Langdon SP, Hendriks HR, Braakhuis B-JM, Pratesi G, Berger DP, Fodstad O, Fiebig HH, and Boven E: Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Annals of Oncology 5: 415-422, 1994.
3. Wittes RE, Critkovich E, and Shah J: Cis-dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treatment Rep 61: 359-366, 1977.
4. Division of Cancer Treatment, NCI Bethesda. Annual Report to the Food and Drug Administration; Diaziquone (AZQ). 1988.
5. Colas C, Fournier J, Pepin O, and et al: Preclinical studies of two ellipticine derivatives. Invest New Drugs 5: 83, 1987.
6. Atassi G, Dumont P, and Pepin O: SR 95325B, a new ellipticine derivative highly active against established murine solid tumors. Proc.Am.Assoc.Cancer Res 30: 617, 1989.
7. LoRusso P, Mucci and Biernat L: Antitumor efficacy of SR 95325B against murine tumor models. Proc Am Assoc Cancer Res 32: 406, 1991.
8. Dorr RT and Von Hoff DD: Cancer Chemotherapy Handbook. Connecticut: Appleton & Lange, 1994.
9. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, and Houghton PJ: Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin.Cancer Res, 4: 743-753, 1998.
10. Rothenberg M: The current status of irinotecan (CPT-11) in the United States. J Clin Oncol 14: 1128-1135, 1996.
11. Colvin OM, Cokgor I, Ashley DM, Kerby T, Arbuck S, Malczyn J, Miller L, Cloughesy T, Houghton PJ, Rich J, Friedman AH, and Friedman HS: Irinotecan treatment of adults with recurrent or progressive malignant glioma. Proc Am Soc Clin Oncology 16: 1998.
12. Gerrits CJH, de Jonge MJA, Schellens JHM, Stoter G and Verweij J: Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76: 952-962, 1997.
13. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW and Houghton JA: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31: 229-239, 1992.
14. Abigerges D, Armand J-P, Chabot GG, and et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446-449, 1994.
15. Cao S, Black JD, Troutt AB and Rustum YM: Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58: 3270-3274, 1998.
16. Kase Y, Hayakawa T, Aburada M, Komatsu Y and Kamataki T: Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol 75: 407-413, 1997.
17. Hardman WE, Moyer MP and Cameron IL: Fish oil supplementation enhanced CPT-11 (Irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side effects. Br J Cancer, In press: 1999